A dose block-randomized, double blinded, placebo controlled, dose-escalation clinical trial to evaluate the safety, tolerability and pharmacokinetics after single oral doses of AVI-CO-004 in healthy male subject
Latest Information Update: 18 Sep 2019
At a glance
- Drugs AVI CO 004 (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors Avixgen
- 11 Nov 2016 Status changed from recruiting to completed.
- 28 Sep 2016 New trial record